Atossa Therapeutics (NASDAQ:ATOS) Stock Passes Above 200 Day Moving Average – Here’s What Happened

Atossa Therapeutics, Inc. (NASDAQ:ATOS) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.39 and traded as high as $1.50. Atossa Therapeutics shares last traded at $1.50, with a volume of 362,114 shares changing hands.

Analyst Ratings Changes

ATOS has been the topic of several analyst reports. StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. Ascendiant Capital Markets lifted their target price on Atossa Therapeutics from $6.25 to $6.50 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Atossa Therapeutics in a research report on Monday, August 12th.

Atossa Therapeutics Stock Performance

The company has a market capitalization of $177.32 million, a P/E ratio of -5.88 and a beta of 1.20. The business has a 50 day moving average of $1.42 and a 200-day moving average of $1.39.

Atossa Therapeutics (NASDAQ:ATOS) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. As a group, equities analysts forecast that Atossa Therapeutics, Inc. will post -0.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Atossa Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock valued at $10,357,000 after buying an additional 78,269 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Atossa Therapeutics by 11.9% in the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock valued at $1,846,000 after acquiring an additional 164,540 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock valued at $490,000 after acquiring an additional 399,041 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Atossa Therapeutics in the second quarter valued at about $161,000. Finally, Virtu Financial LLC bought a new stake in shares of Atossa Therapeutics in the first quarter worth about $151,000. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.